Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

106.12 -0.33 (-0.31%)
Streaming Delayed Price Updated: 1:11 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,122,139
Open 106.45
Bid (Size) 106.09 (400)
Ask (Size) 106.12 (200)
Prev. Close 106.45
Today's Range 106.03 - 107.05
52wk Range 73.31 - 106.95
Shares Outstanding 2,531,374,696
Dividend Yield 3.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a... 
Via PredictStreet
News headline image
Merck & Co. Inc. (NYSE:MRK) Emerges as a Top Quality Investing Candidate ↗
Merck exemplifies quality investing with high ROIC, strong cash flow, and a solid balance sheet, making it a durable long-term healthcare investment candidate. 
Via Chartmill

Performance

YTD
+7.0%
+7.0%
1 Month
+0.4%
+0.4%
3 Month
+36.8%
+36.8%
6 Month
+34.6%
+34.6%
1 Year
+6.3%
+6.3%

More News

Read More
News headline image
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025
Via MarketMinute
Topics Bonds Earnings World Trade
News headline image
Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
Via PredictStreet
Topics Initial Public Offering
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition
Via PredictStreet
Topics Economy
News headline image
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
Via MarketMinute
Topics Intellectual Property
News headline image
Top 5 US Healthcare Stocks By Market Value ↗
Via Stocktwits
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
Via MarketMinute
Topics Economy
News headline image
SCHD vs. NOBL: Different Paths to Dividend Stability ↗
Via The Motley Fool
Topics ETFs
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
Via PredictStreet
Topics Earnings Initial Public Offering Intellectual Property
News headline image
Better Buy in 2026: Pfizer or Merck? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
Via Stocktwits
Topics Government World Trade
News headline image
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck & Co. Inc. (NYSE:MRK) Stands Out as a Durable Dividend Stock ↗
Via Chartmill
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
Via Stocktwits
Topics Economy Government
News headline image
This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'
Via MarketMinute
Topics Artificial Intelligence Economy World Trade

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 106.12
When was Merck & Co last traded?
The last trade of Merck & Co was at 12/26/25 01:11 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 268.63B
How many shares of Merck & Co are outstanding?
Merck & Co has 269B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.